Semaglutide (Ozempic/Wegovy): The Complete 2026 Guide
Semaglutide has reshaped medicine's approach to obesity, type 2 diabetes, and cardiovascular risk in a way few drugs have. Sold as Ozempic for diabetes and Wegovy for weight management, it is now one of the most prescribed medications in the United States — and one of the most discussed. This complete 2026 guide covers everything you need to know: how semaglutide works, who should take it, what side effects to expect, the latest clinical evidence, the compounding pharmacy landscape, and how it compares to tirzepatide.
What Is Semaglutide?
Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist — a class of drugs that mimic a naturally occurring gut hormone called GLP-1. With 94% sequence homology to native human GLP-1, semaglutide activates GLP-1 receptors throughout the body to produce multiple coordinated effects on metabolism.
Two structural modifications set semaglutide apart from earlier GLP-1 drugs like liraglutide. One promotes albumin binding to slow renal clearance; the other shields it from degradation by the enzyme DPP-4. Together, these changes extend semaglutide's half-life to approximately 7 days, enabling once-weekly dosing rather than daily injections.
In December 2025, the FDA approved oral Wegovy tablets — the first GLP-1 pill for obesity — using SNAC technology to facilitate GI absorption. This became commercially available in early 2026, expanding access for patients who prefer not to inject.
How Does Semaglutide Work?
Semaglutide's mechanism is multi-system, which explains why its benefits extend well beyond blood sugar control:
- Pancreas: Stimulates glucose-dependent insulin secretion and suppresses glucagon — insulin only releases when blood sugar is actually elevated, dramatically reducing hypoglycemia risk.
- Brain/Hypothalamus: Acts on appetite-regulating centers to increase satiety and reduce hunger. Patients consistently eat less — not through willpower, but because the brain's hunger drive is genuinely reduced.
- Stomach: Slows gastric emptying, prolonging the feeling of fullness after meals and flattening the post-meal glucose spike.
- Heart and Vasculature: Has direct cardioprotective signaling that appears independent of weight loss — confirmed by the SELECT trial.
- Liver and Kidneys: Reduces hepatic fat accumulation and shows emerging kidney-protective effects.
FDA-Approved Doses and Dosing Schedules
Ozempic (Type 2 Diabetes & CV Risk Reduction)
Ozempic is FDA-approved for glycemic control in type 2 diabetes and for reducing major adverse cardiovascular events (MACE) in adults with T2D and established CVD.
| Phase | Dose | Duration |
|---|---|---|
| Initiation | 0.25 mg once weekly | 4 weeks |
| Step-up | 0.5 mg once weekly | 4+ weeks |
| Maintenance | 0.5 mg, 1 mg, or 2 mg once weekly | Ongoing |
| Maximum | 2 mg once weekly | — |
Wegovy Injectable (Chronic Weight Management)
Wegovy is FDA-approved for adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity. Also approved for adolescents aged 12 and older meeting BMI criteria.
| Phase | Dose | Duration |
|---|---|---|
| Step 1 | 0.25 mg once weekly | 4 weeks |
| Step 2 | 0.5 mg once weekly | 4 weeks |
| Step 3 | 1 mg once weekly | 4 weeks |
| Step 4 | 1.7 mg once weekly | 4 weeks |
| Maintenance | 2.4 mg once weekly | Ongoing |
Wegovy Oral Tablets (NEW — Approved December 2025)
Must be taken on an empty stomach with up to 4 oz of plain water only; wait 30 minutes before eating or drinking anything else.
| Phase | Dose | Duration |
|---|---|---|
| Step 1 | 1.5 mg once daily | 30 days |
| Step 2 | 4 mg once daily | 30 days |
| Step 3 | 9 mg once daily | 30 days |
| Maintenance | 25 mg once daily | Ongoing |
Side Effects: What to Expect
Common Side Effects
Gastrointestinal effects are by far the most common, especially during dose escalation. They typically peak in the first 4–12 weeks:
- Nausea: Affects 2–20% of patients — most common symptom
- Diarrhea: ~10–13% of patients
- Vomiting: ~5–10%
- Constipation: More common at higher doses
Tip: Eat smaller low-fat meals, stay hydrated, and consider injecting at night so peak nausea occurs during sleep.
Serious Risks
Thyroid C-Cell Tumors (Black Box Warning): Based on rodent studies. Multiple systematic reviews through 2026 found no increased risk in human populations. Contraindicated in anyone with personal/family history of medullary thyroid carcinoma (MTC) or MEN type 2.
Pancreatitis: Documented in ~0.24% of trial participants. Discontinue for persistent severe abdominal pain.
Gastroparesis: Can become severe enough to be classified as drug-induced gastroparesis. Avoid in pre-existing severe gastroparesis.
Gallbladder Disease: Increased risk of gallstones, possibly related to rapid weight loss.
Acute Kidney Injury: Usually secondary to dehydration from GI adverse effects — stay well hydrated.
What the Clinical Evidence Shows
Weight Loss: STEP Trial Program
- STEP 1 (68 weeks): Mean weight loss of 14.9% body weight vs. 2.4% placebo; 69–79% achieved ≥10% weight loss
- STEP 5 (2 years): Weight loss sustained at −15.2% — demonstrating durable efficacy with continued treatment
- STEP UP (2025 — 7.2 mg dose): Average of 20.7% body weight lost at 72 weeks; not yet FDA-approved
Important: When semaglutide is discontinued, patients regain approximately two-thirds of lost weight within one year (STEP 4). This is a long-term treatment, not a short-term fix.
Cardiovascular Benefits: The SELECT Trial
The SELECT trial enrolled 17,604 adults aged ≥45 with preexisting CVD, BMI ≥27, and no diabetes — the first major cardiovascular outcomes trial in an obese/overweight population without T2D.
- 20% relative risk reduction in MACE (CV death, non-fatal MI, non-fatal stroke): 6.5% semaglutide vs. 8.0% placebo (HR 0.80; p<0.001)
- Mean follow-up: ~39.8 months; mean weight loss in the trial: 9.4%
A 2025 Lancet analysis found the cardiovascular benefit was largely independent of weight loss — suggesting direct cardioprotective mechanisms including anti-inflammatory effects and arterial plaque modulation beyond adiposity reduction. This finding led to a 2024 FDA label update: Wegovy is now approved for CV risk reduction in adults with established CVD and obesity/overweight, even without diabetes.
Compounded Semaglutide: The 2026 Regulatory Picture
Background
From 2022 through early 2025, semaglutide's position on the FDA Drug Shortage List allowed both 503A compounding pharmacies and 503B outsourcing facilities to legally compound it — creating a market of $99–$299/month alternatives to $1,300+ brand-name products.
The Shortage Was Resolved — February 2025
On February 21, 2025, the FDA declared the semaglutide shortage resolved. A federal court in April 2025 denied the compounding industry's injunction attempt to block this finding, removing the primary legal basis for most compounding.
Current Status (May 2026)
- 503A pharmacies: April 2026 FDA clarification limits them to no more than four prescriptions of a given semaglutide preparation per calendar month.
- 503B outsourcing facilities: On April 30, 2026, the FDA proposed to formally exclude semaglutide, tirzepatide, and liraglutide from the 503B bulk substances list. Public comment period runs through June 29, 2026.
- Safety concerns: The FDA has flagged compounded semaglutide products for incorrect concentrations and dosing errors. If pursuing compounded options, use only an accredited 503A pharmacy requiring a valid prescription.
The bottom line: compounded semaglutide's legal window is closing. Patients using compounded formulations should have a transition plan with their prescriber.
Semaglutide vs. Tirzepatide
| Feature | Semaglutide (Wegovy/Ozempic) | Tirzepatide (Zepbound/Mounjaro) |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | Dual GLP-1 + GIP receptor agonist |
| Max approved dose (weight) | 2.4 mg/week or 25 mg/day (oral) | 15 mg/week |
| Pivotal trial weight loss | ~15% at 68 weeks (STEP 1) | ~22.5% at 72 weeks (SURMOUNT-1) |
| Head-to-head (SURMOUNT-5) | Reference arm | ~47% more weight loss |
| CV outcomes | SELECT: 20% MACE reduction (robust) | Pivotal trial pending |
| Brand cost (no insurance) | ~$1,350–$1,643/month | ~$1,060–$1,350/month |
Tirzepatide produces greater weight loss (~47% more in SURMOUNT-5). Semaglutide has the stronger cardiovascular evidence base from SELECT. The choice often comes down to primary goal: maximal weight loss favors tirzepatide; established CVD with the deepest evidence base favors semaglutide.
Who Is a Candidate?
Wegovy (weight management): Adults with BMI ≥30; adults with BMI ≥27 plus a weight-related comorbidity; adolescents ≥12 meeting BMI criteria; adults with established CVD and obesity/overweight (CV indication).
Ozempic (type 2 diabetes): Adults with T2D; adults with T2D and established CVD.
Contraindications: Personal/family history of MTC or MEN 2; hypersensitivity to semaglutide; pregnancy; severe gastroparesis.
Storage and Injection Tips
- Storage before first use: Refrigerate at 36–46°F (2–8°C). Never freeze.
- After first use — Ozempic: Up to 56 days at room temperature or refrigerated
- After first use — Wegovy: Up to 28 days at room temperature or refrigerated
- Injection sites: Abdomen, upper thigh, or upper arm. Rotate weekly.
- Missed dose: Inject within 5 days. If over 5 days have passed, skip and resume on schedule.
Cost and Coverage in 2026
- Ozempic retail: ~$1,394/month; savings programs: as low as $199/month
- Wegovy injectable retail: ~$1,350–$1,643/month; savings programs: as low as $149/month
- Wegovy oral: ~$149–$299/month through GoodRx self-pay programs
- Insurance: Ozempic commonly covered for T2D; Wegovy for obesity alone increasingly excluded. Medicare covers Wegovy for the CV indication.
The Bottom Line
Semaglutide is a genuinely transformative medication — not just for weight loss, but for cardiovascular risk reduction and metabolic health. The SELECT trial's finding that CV benefit is largely independent of weight lost suggests semaglutide's effects run deeper than the scale.
Two major 2025–2026 developments define the current landscape: oral Wegovy expanding access for needle-averse patients, and the closing regulatory window for compounded semaglutide. For most patients, these are long-term treatments — the weight regain data on stopping underscores that the conversation with your prescriber should address sustained use from the start.
This article is for educational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting, stopping, or changing any medication.